We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
On June 25, Aidea Pharmaceutical obtained approval for the marketing application of a new Class 1 drug ACC007 for the treatment of HIV-1 infection submitted by CDE of NMPA of China.